+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Monkeypox Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F- Product Image
Monkeypox Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F- Product Image
New

Monkeypox Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • PDF Icon

    Report

  • 185 Pages
  • November 2025
  • Region: Global
  • TechSci Research
  • ID: 5636261
Free Webex Call
10% Free customization
Description Jump to:

Smallpox Vaccine is the fastest growing segment, North America is the largest regional market

Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

 10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Global Monkeypox Therapeutics Market, valued at USD 87.00 Million in 2024, is projected to experience a CAGR of 9.01% to reach USD 145.99 Million by 2030. Monkeypox therapeutics encompass pharmaceutical interventions, including antiviral drugs and vaccines, primarily utilized for the prevention and treatment of monkeypox virus infections. These interventions address the zoonotic disease characterized by smallpox-like symptoms. The global market for these therapeutics is driven by the increasing incidence of monkeypox outbreaks in various regions. Further impetus stems from governmental initiatives prioritizing public health preparedness, which includes the strategic stockpiling of antiviral treatments and vaccines.

Key Market Drivers

The increasing global incidence of monkeypox outbreaks profoundly influences the therapeutics market by creating an urgent and sustained demand for effective treatments and preventative measures. Each new surge in cases directly translates into a heightened need for antiviral drugs and vaccines to manage symptoms, prevent severe disease, and curb transmission.

According to the Pan American Health Organization/WHO, in October 2024, an Epidemiological Update reported 109,699 confirmed cases of mpox globally between January 2022 and September 30, 2024, further indicating a monthly increase of 8% in new cases in September 2024 compared to August, underscoring the ongoing spread of the virus and the persistent threat it poses to public health. This rising incidence drives pharmaceutical companies to allocate resources towards research and development, aiming to innovate and expand their portfolio of monkeypox therapeutics.

Key Market Challenges

The limited availability of specifically approved therapeutic agents for monkeypox presents a substantial challenge to the growth of the Global Monkeypox Therapeutics Market. Current treatment protocols frequently depend on drugs originally developed for smallpox, which may not consistently prove optimal or widely accessible for monkeypox virus infections. This reliance creates a significant barrier to the rapid and widespread deployment of tailored interventions, particularly when considering evolving viral clades and diverse geographical spread.

Key Market Trends

The global monkeypox therapeutics market is experiencing significant evolution, driven by shifts in drug development and preventative strategies. One prominent trend is the **Evolution Towards Oral Antiviral Therapeutic Options**. This movement is crucial for improving patient access, adherence, and facilitating outpatient care, thereby easing the burden on healthcare infrastructure.

Oral formulations offer a more convenient alternative to intravenous treatments, which can be critical during outbreaks. For example, NanoViricides, Inc. announced in July 2025 the near-finalization of its adaptive Phase II clinical trial protocol for NV-387, a novel oral antiviral designed to treat monkeypox virus infections, highlighting the ongoing efforts to develop user-friendly treatment options. This aligns with a broader pharmaceutical industry trend where oral drug development remains a priority due to its patient-centric benefits.

Key Market Players Profiled:

  • Chimerix Inc.
  • SIGA Technologies, Inc.
  • Emergent BioSolutions Inc.
  • Bavarian Nordic A/S
  • Hetero Drugs Limited
  • Mylan N.V.
  • Piramal Enterprises Limited
  • Olon S.p.A.
  • Teva Pharmaceutical Industries Limited
  • CIDIC Company Limited

Report Scope:

In this report, the Global Monkeypox Therapeutics Market has been segmented into the following categories:

By Treatment:

  • Smallpox Vaccine
  • Antivirals
  • Vaccinia Immune Globulin (VIG)

By End User:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others

By Region:

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Monkeypox Therapeutics Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Monkeypox Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin (VIG))
5.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Monkeypox Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment
6.2.2. By End User
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Monkeypox Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment
6.3.1.2.2. By End User
6.3.2. Canada Monkeypox Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment
6.3.2.2.2. By End User
6.3.3. Mexico Monkeypox Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment
6.3.3.2.2. By End User
7. Europe Monkeypox Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment
7.2.2. By End User
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Monkeypox Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment
7.3.1.2.2. By End User
7.3.2. France Monkeypox Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment
7.3.2.2.2. By End User
7.3.3. United Kingdom Monkeypox Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment
7.3.3.2.2. By End User
7.3.4. Italy Monkeypox Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Treatment
7.3.4.2.2. By End User
7.3.5. Spain Monkeypox Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Treatment
7.3.5.2.2. By End User
8. Asia-Pacific Monkeypox Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment
8.2.2. By End User
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Monkeypox Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment
8.3.1.2.2. By End User
8.3.2. India Monkeypox Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment
8.3.2.2.2. By End User
8.3.3. Japan Monkeypox Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment
8.3.3.2.2. By End User
8.3.4. South Korea Monkeypox Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Treatment
8.3.4.2.2. By End User
8.3.5. Australia Monkeypox Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Treatment
8.3.5.2.2. By End User
9. Middle East & Africa Monkeypox Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment
9.2.2. By End User
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Monkeypox Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment
9.3.1.2.2. By End User
9.3.2. UAE Monkeypox Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment
9.3.2.2.2. By End User
9.3.3. South Africa Monkeypox Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment
9.3.3.2.2. By End User
10. South America Monkeypox Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment
10.2.2. By End User
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Monkeypox Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Treatment
10.3.1.2.2. By End User
10.3.2. Colombia Monkeypox Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Treatment
10.3.2.2.2. By End User
10.3.3. Argentina Monkeypox Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Treatment
10.3.3.2.2. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Monkeypox Therapeutics Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Chimerix Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. SIGA Technologies, Inc.
15.3. Emergent BioSolutions Inc.
15.4. Bavarian Nordic A/S
15.5. Hetero Drugs Limited
15.6. Mylan N.V.
15.7. Piramal Enterprises Limited
15.8. Olon S.p.A.
15.9. Teva Pharmaceutical Industries Limited
15.10. CIDIC Company Limited
16. Strategic Recommendations17. About the Publisher & Disclaimer

Companies Mentioned

The companies profiled in this Monkeypox Therapeutics market report include:
  • Chimerix Inc.
  • SIGA Technologies, Inc.
  • Emergent BioSolutions Inc.
  • Bavarian Nordic A/S
  • Hetero Drugs Limited
  • Mylan N.V.
  • Piramal Enterprises Limited
  • Olon S.p.A.
  • Teva Pharmaceutical Industries Limited
  • CIDIC Company Limited

Table Information

Report AttributeDetails
No. of Pages185
PublishedNovember 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 87 Million
Forecasted Market Value ( USD ) by 2030 $ 145.99 Million
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Monkeypox - Pipeline Insight, 2025 - Product Image

Monkeypox - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Monkey Pox Treatment Market Report 2025 - Product Image

Monkey Pox Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Mpox Therapeutics Market - Global Strategic Business Report - Product Image

Mpox Therapeutics Market - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
Smallpox - Pipeline Insight, 2025 - Product Image

Smallpox - Pipeline Insight, 2025

  • Clinical Trials
  • 40 Pages
  • Global
From
Smallpox Treatment - Global Strategic Business Report - Product Image

Smallpox Treatment - Global Strategic Business Report

  • Report
  • 320 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.